Belite Bio (BLTE) to Release Quarterly Earnings on Monday

Belite Bio (NASDAQ:BLTE) is anticipated to announce its Q1 2025 earnings results before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($0.37) per share for the quarter.

Belite Bio (NASDAQ:BLTE) last released its earnings results on Monday, March 17th. The company reported ($0.32) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.02). On average, analysts expect Belite Bio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Belite Bio Stock Performance

Shares of BLTE stock opened at $61.03 on Friday. The stock has a 50 day moving average price of $61.90 and a 200 day moving average price of $63.18. The firm has a market capitalization of $1.94 billion, a P/E ratio of -54.98 and a beta of -1.48. Belite Bio has a 52-week low of $40.00 and a 52-week high of $86.53.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on BLTE. HC Wainwright reiterated a “buy” rating and set a $100.00 price objective on shares of Belite Bio in a report on Tuesday, March 18th. Benchmark reaffirmed a “buy” rating and set a $80.00 price target on shares of Belite Bio in a research note on Wednesday, March 26th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Belite Bio in a research note on Tuesday, March 18th.

About Belite Bio

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company’s lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.